CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIMENHYDRIN	OTHER COMP	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATE TABLETS	ONENTS/ *8-Chlorotheophylline*							Change C_U = nominal concentration of dimenhydrinate in the *Sample solution* (mg/mL) to: C_U = determined concentration of dimenhydrinate in the *Sample solution*, as obtained in the *Assay* (mg/mL)
AZITHROMYCIN FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In USP Azithromycin Related Compound F RS: Change 762.97 to: 762.98 AND In USP Desosaminylazithromycin RS: Change 590.79 to: 590.80

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATRACURIUM BESYLATE	CHEMICAL INFORMATION	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimeth oxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester to: 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
CARBAMAZEPINE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In USP Carbamazepine Related Compound A RS: Change 238.28 to: 238.29 AND In USP Carbamazepine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BOTANICAL EXTRACTS	PREPARATIONS	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Related Compound B RS: Change 193.24 to: 193.25 AND In USP 9-Methylacridine RS: Change 193.24 to: 193.25 In *General Pharmacopeial Requirements/Pesticide Residues*: Change where *L* is the limit in the original article as listed in *Table 4* (see *Pesticide Residue Analysis* under *Articles of Botanical Origin*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<561>) to: where *L* is the limit in the original article as listed in *Table 5* (see *Pesticide Residue Analysis* under *Articles of Botanical Origin <561>*)
DOXYCYCLINE HYCLATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In USP Doxycycline Related Compound A RS: Change 444.43 to: 444.44 AND Change 480.13 to: 480.90
MUPIROCIN NASAL OINTMENT	*Related compounds/Table 1*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote 2: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
ACYCLOVIR	ASSAY/ *Procedure*	*USPNF Online*	Online	29-Apr-2022	1-May-2023	*NA*	*NA*	In the *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change 0.1 N sodium hydroxide to: 0.01 N sodium hydroxide
DACARBAZINE FOR INJECTION	IMPURITIES	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Delete *Limit of 2-Azahypoxanthine* test
MUPIROCIN OINTMENT	IMPURITIES/*Organic Impurities*/*Table 2*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote b: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
MECAMYLAMINE HYDROCHLORIDE	*USP Reference standards* <11>	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In USP Mecamylamine Related Compound A RS: Change *N*,1,7,7-Tetramethyl bicyclo [2.2.1]heptan-2-amine. $C_{11}H_{21}N$ 167.29 to: *N*,1,7,7-Tetramethylbicyclo[2.2.1]heptan-2-amine hydrochloride. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MUPIROCIN CALCIUM	CHEMICAL INFORMATION	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	$_{11}H_{21}N \cdot HCl$ 203.75 Change 1075.34 to: 1075.35
CHROMATOGRAPHY	ADJUSTMENT OF CHROMATOGRAPHIC CONDITIONS	*USPNF Online*	Online	29-Apr-2022	1-Dec-2022	*NA*	*NA*	In *Liquid Chromatography: Isocratic Elution/Injection volume*: Change Result = (V_{inj2} = V_{inj1} (L_2 d_{c2}^2)/(L_1 d_{c1}^2) to: $V_{inj2} = V_{inj1}$ (L_2 d_{c2}^2)/(L_1 d_{c1}^2) AND In *Liquid Chromatography: Gradient Elution/Column parameters and flow rate*: Change $F_2 = F_2 \times [(dc_2^2 \times dp_1)/(dc_1^2 \times dp_2)]$ to: $F_2 = F_1 \times [(dc_2^2$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								× dp_1)/(dc_1^2 × dp_2)]
MUPIROCIN CREAM	*Related compounds/Table 1*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote 2: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
BROMOCRIPTINE MESYLATE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In *Analysis*: Change bromocriptine mesylate ($C_{32}H_{40}BrN_5O_5 \cdot CH_4SO_3$) to: bromocriptine ($C_{32}H_{40}BrN_5O_5$) AND In *Tolerances*: Change bromocriptine mesylate ($C_{32}H_{40}BrN_5O_5 \cdot CH_4SO_3$) to: bromocriptine ($C_{32}H_{40}BrN_5O_5$)
DACARBAZINE FOR INJECTION	IDENTIFICATION	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Delete Identification test *C*
MUPIROCIN CALCIUM	IMPURITIES/*Organic Impurities*/*Table*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote b: Change 9-{(*E*)-4-[(2*R*,3a*S*,6

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	1							*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
ONDANSETRO	*USP Reference*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N ORAL SOLUTION	*standards <11>*							USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								met hylene-4*H*-carbazol-4-one. to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one. USP Ondansetron

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Related Compound D RS 9-Methyl-3-methylene-1,2,3,9-tetra hydro-4*H*-carbazol-4-one.
ACYCLOVIR FOR INJECTION	IMPURITIES/ *Procedure*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Standard solution A*: Change 0.5 ?g/mL of *Acyclovir standard solution* in *Solution A* to: 0.5 ?g/mL of USP Acyclovir RS from *Acyclovir standard solution* in *Solution A* AND In *Standard solution B*: Change 5 ?g/mL of *Guanine*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution in *Solution A* to: 5 ?g/mL of guanine from *Guanine solution* in *Solution A* AND In *Analysis 1*: Change r_S = peak response of guanine in the *Standard solution* C_S = concentration of guanine in the *Standard solution* to: r_S = peak response of guanine in *Standard solution B* C_S = concentration of guanine in *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution B AND In *Analysis 2*: Change r_S = peak response of acyclovir in the *Standard solution* C_S = concentration of USP Acyclovir RS in the *Standard solution* (mg/mL) to: r_S = peak response of acyclovir in *Standard solution A* C_S = concentration of USP Acyclovir RS in *Standard solution A* (mg/mL)
CHROMATOGRAPHY	SYSTEM SUITABILITY	*USPNF Online*	Online	25-Mar-2022	1-Dec-2022	*NA*	*NA*	Change **System Repeatability—Assay**

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of an Active Substance or an Excipient to: **System Repeatability**
DIBASIC POTASSIUM PHOSPHATE	ASSAY/ *Procedure*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Analysis*: Change Titrate the *Blank* with 1 N sodium hydroxide VS, and record the volume of 1 N sodium hydroxide VS consumed. Titrate the excess acid in the *Sample solution* with 1 N sodium hydroxide VS to the inflection point at pH 4, and record the buret reading. to: Titrate the *Blank* potentiom etrically with 1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N sodium hydroxide VS, and record the volume of 1 N sodium hydroxide VS consumed. Titrate the excess acid in the *Sample solution* potentiometrically with 1 N sodium hydroxide VS to the inflection point at pH 4, and record the buret reading.
ONDANSETRON TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Table 1*/footnotes: Change [b] 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. [c] 1,2,3,9-Tetrahy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dro-9-methyl-3-met hylene-4*H* -carbazol-4-one .[d]
								3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H* -carbazol-4-one .[e]
								1,2,3,9-Tetrahydro-9-methyl-3-[1*H* -imidazol-1-yl)methyl]-4*H* -carbazol-4-one .[to:][b]
								9-Methyl-1,2,3,9-tet rahydr o-4*H* -carbazol-4-one .[c]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.[d]
								3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.[e]
								3-[(1*H*-Imidazol-1-yl)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.
POWDERED VALERIAN EXTRACT	DEFINITION	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid, on the dried basis. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid, on the anhydrous basis.
PANTOPRAZOLE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In USP Pantoprazole Related Compound ERS: Change A mixture of the stereoisomers of 6,6?-bis(difluoromethoxy)-2,2?-bis[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1*H*,1?*H*-5,5?-bibenzimidazolyl. to: 6,6?-Bis(difluoromethoxy)-2,2?-bis[[(3,4-dimethoxypyridin-2-yl)me th

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl]s ulfinyl]-1*H*,1?*H*-5,5?-bibenzimidazole.
CORN STARCH	IM PURITIES/*Limit of Sulfur Dioxide*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Bromophenol blue indicator solution*: Change 0.2 mg/mL of bromophenol blue in dilute alcohol. Filter if necessary. to: Dissolve 100 mg of bromophenol blue in 100 mL of dilute alcohol (1 in 5), and filter if necessary.
ONDANSETRON TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-1,2,3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride.
POWDERED VALERIAN EXTRACT	COMPOSITION /*Content of Valerenic Acids*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Acceptance criteria*: Change calculated as the sum of hydroxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid on the dried basis to: calculated as the sum of hydr

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxyvalerenic acid, acetoxyvalerenic acid, and valerenic acid on the anhydrous basis
MAGNESIUM OXIDE	IM PURITIES/*Limit of Calcium*	*USPNF Online*	Online	25-Feb-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of Magnesium Hydroxide in the *Sample solution* (mg/mL) to: C_U = concentration of Magnesium Oxide in the *Sample solution* (mg/mL)
IODIXANOL	IM PURITIES/*Limit of 2-Methoxyethanol*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Standard stock solution*: Change 0.005 mg/mL of methanol and 0.01 mg each of isopropyl alcohol, secondary butyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								alcohol, and 2-methoxyethanol in *Internal standard solution* to: 0.005 mg/mL of methanol and 0.01 mg/mL each of isopropyl alcohol, secondary butyl alcohol, and 2-methoxyethanol in *Internal standard solution*
PROPYLENE GLYCOL DIACETATE	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change r_S = sum of all the peak areas, excluding the solvent peaks from the *Standard solution* to: r_S = sum of all the peak areas, excluding the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solvent peaks from the *Sample solution*
ZOLEDRONIC ACID	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change r_U = peak response of zoledronic acid from the *Sample solution* to: r_U = peak response of any individual impurity from the *Sample solution*
ECONAZOLE NITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In USP Econazole Related Compound B RS: Change Econazole amine; 2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethanamine. $C_{15}H_{14}Cl_3NO$ 330.64 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRAZODONE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	Econazole amine; 2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethanamine nitrate. $C_{15}H_{14}Cl_3NO \cdot HNO_3$ 393.65 In footnote f of *Table 2*: Change 1,1-Bis{2-chloro-[4-(3-{1,2,4-triazolo[4,3-*a*]pyridin-3-(2*H*)-on-2-yl}propyl)piperazine-1-yl]phenyl}ethane trihydrochloride. to: 2,2'-{[Ethane-1,1-diylbis(3-chloro-4,1-phenylene)bis(piperazine-4,1-diyl)]bis(propane-3,1-diyl)}bis([1,2,4]triazolo[4,3-*a*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]pyri din-3(2*H*)-one).
BEHENOYL POLYOXYLGLYCERIDES	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USPNF Online*	Online	25-Feb-2022	1-Mar-2022	*NA*	*NA*	In *Analysis*: Change If the volume of 0.5 N sodium hydroxide VS required for the titration is less than 2 mL, to: If the volume of 0.5 N alcoholic potassium hydroxide VS required for the titration is less than 2 mL,
ONDANSETRON ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{16}H_{20}N_2O$ · HCl 292.80 to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. $C_{16}H_{20}N_2O$ · HCl 292.81 AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVOFLOXACIN	IMPURITIES/*Organic Impurities, Procedure 1*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	. Change **Solution A**, **Mobile phase**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **Sample solution**, and **Chromatographic system**: Proceed as directed in the *Assay*.
FULVESTRANT	*Related compounds*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In footnote 1 of table: Change Estra-1,3,5(10)-triene-6-one-3,17-diol,7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-6-one-3,17?-diol AND In footnote 2: Change Estra-1,3,5(10),6-tetraene-3,17-diol,7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10),6-tetraene-3,17?-diol AND In footnote 3: Change Estra-1,3,5(10)-triene-3,17-diol,7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]nonyl]-(7?,17?) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfonyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol AND In footnote 4: Change Estra-1,3,5(10)-triene-3,17-diol, 7-{9-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonylsulfinyl]nonyl}-(7?,17?) to: 7?-{9-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonylsulfinyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol AND In footnote 5: Change 7,7-Nonamethylene-bis(estra-1,3,5(10)-triene-3,17-diol-(7?,17?)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 7?,7?-Nonamethylenebis[estra-1,3,5(10)-triene-3,17?-diol] AND In footnote 6: Change Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol
ONDANSETRON HYDROCHLORIDE	*USP Reference standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 9-Methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.
WARFARIN SODIUM FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Warfarin Related Compound A RS: Change 3-(*o*-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. to: 3-(2-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-o

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ne. AND Change 264.33 to: 264.32
SORAFENIB TABLETS	PERFORMANCE TESTS/ *Dissolution* <*711*>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Tolerances*: Change NLT 75 (*Q*) of the labeled amount of sorafenib ($C_{21}H_{16}ClF_3N_4O_3$) is dissolved. to: NLT 75% (*Q*) of the labeled amount of sorafenib ($C_{21}H_{16}ClF_3N_4O_3$) is dissolved.
ORPHENADRINE CITRATE INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Orphenadrine Related Compound B RS: Change *N*-Ethyl-*N*,*N*-dimethyl [2-2(methylbenzhydryloxy)ethyl]ammonium chloride;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								also known as *N*-ethyl-*N*,*N*-dimethyl-2-[phenyl(*o*-tolyl)methoxy]ethanaminium chloride. to: *N*-Ethyl-*N*,*N*-dimethyl [2-(2-methylbenzhydryloxy)ethyl]ammonium chloride; also known as *N*-Ethyl-*N*,*N*-dimethyl-2-[phenyl(2-tolyl)methoxy]ethanaminium chloride.
NICARDIPINE HYDROCHLORIDE INJECTION	DEFINITION	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	Change NTL 90.0% to: NLT 90.0%
AMLODIPINE BESYLATE	*Assay*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Chromatographic system*: Change Chromatograph the *Standard preparation*, and record the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peak responses as directed for *Procedure*: the standard deviation for replicate injections is not more than 2.0%. to: Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 2.0%.
ONDANSETRON INJECTION	*USP Reference standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 9-Methyl-1,2,3,9-tetrahydro-4*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carbazol-4-one . AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one . to: 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one .
LORATADINE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Tier 1*/*Solution A* and *Tier 2*/*Solution B*: Change Tween 20 to: polysorbate 20
FULVESTRANT	CHEMICAL	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	INFORMATION							606.77 to: 606.78
ORPHENADRINE CITRATE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Orphenadrine Related Compound B RS: Change *N*-Ethyl-*N*,*N*-dimethyl [2-2(methylbenzhydryloxy)ethyl]ammonium chloride; Also known as *N*-Ethyl-*N*,*N*-dimethyl-2-[phenyl(*o*-tolyl)methoxy]ethanaminium chloride. to: *N*-Ethyl-*N*,*N*-dimethyl [2-(2-methylbenzhydryloxy)ethyl]ammonium chloride; also known as *N*-Ethyl-*N*,*N*-dimethyl-2-[phenyl(2-tolyl)methoxy]ethanamini

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								um chloride.
WARFARIN SODIUM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Warfarin Related Compound A RS: Change 3-(*o*-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. to: 3-(2-Hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one. AND Change 264.33 to: 264.32
AMLODIPINE BESYLATE	*Related compounds/Test 2*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Chromatographic system*: Change Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the standard

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								deviation for replicate injections is not more than 10.0%. to: Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the relative standard deviation for replicate injections is not more than 10.0%.
ONDANSETRON	*USP Reference standards <11>*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	Change USP Ondansetron RS USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahyd

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ro- 9-me thyl-4*H* -carbazol-4-one . USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahy dro-9-methyl-3- met hylene- 4*H* -carbazol-4-one . to: USP Ondansetron RS USP Ondansetron Related Compound A RS 3-[(Dimethylami no)methyl]-9-m ethyl-1,2,3,9-tet rahydr o-4*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 3

- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- …
- Next page Next ›
- Last page Last »